Guido Oelkers - Swedish Orphan Insider

BIOVF -- USA Stock  

USD 29.50  1.05  3.69%

  CEO
Dr. Guido Oelkers, Ph.D. was appointed President and Chief Executive Officer at Swedish Orphan Biovitrum AB, effective as of May 22, 2017. He holds PhD in Strategic Management, University of South Australia, Master of Economics, South Bank University, London, Complementary studies in Economics, London School of Economics and Political Science. He is Board member of Sartorius AG. Previously, he was CEO, BSN Medical Board member Meda President CEO, Gambro AB and held executive roles in Nycomed, Invida Holding and DKSH Group. He also held various country management positions in Aventis.
Age: 52  CEO Since 2017      
46 86 97 20 00  http://www.sobi.com

Management Efficiency

The company has return on total asset (ROA) of 13.63 % which means that it generated profit of $13.63 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 27.22 % meaning that it generated $27.22 on every $100 dollars invested by stockholders.
The company has accumulated 788.2 K in total debt. Swedish Orphan Biovitrum AB has Current Ratio of 1.96 which is within standard range for the sector.

Similar Executives

Found 6 records

CEO Since

Leonard SchleiferRegeneron Pharmaceuticals
1994
Paul PerreaultCSL Limited
2013
Perry KarsenCelgene Corporation
N/A
Flemming OrnskovShire plc
2013
George ScangosBiogen
N/A
Lars SoerensenNovo Nordisk AS
2015

Entity Summary

Swedish Orphan Biovitrum AB , an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. Swedish Orphan Biovitrum AB is headquartered in Solna, Sweden. Swedish Orphan is traded on OTC Market in USA.Swedish Orphan Biovitrum AB (BIOVF) is traded on OTC Market in USA. It is located in Tomtebodav?gen 23A and employs 842 people.

Swedish Orphan Biovi Leadership Team

Hans Wigzell, Independent Director
Lennart Johansson, Director
Annette Clancy, Independent Director
Trista Morrison, Vice President - Communications for North America
Kirsti Gjellan, Senior Vice President Manufacturing Operations
Jorgen Winroth, Head of Investor Relations and VP
Milan Zdravkovic, Senior Vice President Head of Research & Development
Rami Levin, Head of North America
Norbert Oppitz, Head of Specialty Care
Hans Schikan, Independent Director
Dennis Pedersen, Senior Vice President Human Resources
Helena Saxon, Director
Anders Edvell, Head of Marketing and Sales
Philip Wood, Head of Haemophilia
Geoffrey McDonough, CEO
Lars Dreioee, Senior Vice President Chief Quality & Compliance Officer
Alan Raffensperger, COO and Sr. VP
Fredrik Berg, Head of Legal and Intellectual Property, Risk- Safety and Environment Management and General Counsel
Fredrik Wetterlundh, Head of Human Resources
BoGunnar Rosenbrand, Director, Employee Representative
Adine Axen, Independent Director
Birgitte Volck, Senior Vice President Chief Medical Officer
MatsOlof Wallin, CFO, Senior Vice President
Stefan Fraenkel, Vice President Head of Corporate Development
Hakan Bjorklund, Independent Chairman of the Board
Cecilia Forberg, Vice President Head of Project and Portfolio Management
Stephen James, Vice President Head of Drug Design and Development
Bo Hansen, Chairman of the Board
Armin Reininger, Senior Vice President Head of Global Medical and Scientific Affairs
Hege Hellstrom, Head of EMENAR
Catarina Larsson, Director, Employee Representative
Henrik Stenqvist, CFO
David Allsop, Director
Elisabeth Svanberg, Director
Torbjorn Hallberg, General Counsel and Head of Legal Affairs
Wills HughesWilson, Senior Vice President and Chief Patient Access Officer
Guido Oelkers, President CEO
Pia Axelsson, Director, Employee Representative
Jeffrey Jonas, Independent Director
Matthew Gantz, Director
Theresa Heggie, Independent Director

Stock Performance Indicators

Current Sentiment - BIOVF

Swedish Orphan Biovi Investor Sentiment

Macroaxis portfolio users are unresponsive in their opinion about investing in Swedish Orphan Biovitrum AB. What is your outlook on investing in Swedish Orphan Biovitrum AB? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Swedish Orphan Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Swedish Orphan and Amgen. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Chance of Distress module to get analysis of equity chance of financial distress in the next 2 years.
Search macroaxis.com